Data reported in SITC abstracts show single-digit percentage responses

With GV joining investor syndicate, the biotech’s ‘non-linear’ path will include HPK1 program rivaling Pfizer’s, as well as immunology and metabolic assets

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 

Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) exercised its option to license from Bicycle Therapeutics Inc. (NASDAQ:BCYC) tissue -targeted delivery vehicles for oligonucleotide therapeutics that use a

Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders

As the technology goes mainstream, next-gen molecules will use new enzymes, tap new pathways, and address PK/PD challenges